

Zofran Lawsuit Plaintiff Claims Infant?s Cleft Palate, Clubfoot, And Respiratory Distress Caused By Drug Exposure

April 20, 2016

April 20, 2016 - PRESSADVANTAGE -

ZofranLegal.com reports on another lawsuit which has been filed by a woman from Arkansas against Zofran manufacturer and corporate giant GlaxoSmithKline. In the lawsuit, the woman alleges that after fetal exposure to Zofran, her unborn son developed multiple birth defects including cleft palate, clubfoot, and respiratory distress syndrome.

The woman?s son was exposed to the drug through her while growing in utero as the mother was reportedly prescribed anti-nausea drug Zofran to treat her morning sickness symptoms. The woman states that she used Zofran throughout her first trimester. She also states that after being exposed to Zofran and then being born in 2007, her son required multiple surgeries to repair several congenital birth defects.

Additional lawsuit details note that the mother took Zofran during just one of her 3 pregnancies, and that this pregnancy was the only one to result in a child with birth defects. Women frequently suffer from morning sickness during their first trimester, however, this is also a critical time of cell division for the fetus, when it forms much of its initial limb, mouth, and heart tissue.

Unfortunately, this mother is not alone in her claims. She is joined by hundreds of other parents from across

the U.S. who similarly claim that their children have developed birth defects due to Zofran exposure. This

growing number of Zofran birth defect lawsuits involve allegations that fetal exposure to the drug caused

infants to develop a range of severe and sometimes fatal defects, including clubfoot, cleft lip and palate,

transposition of the greater vessels, tetralogy of fallot, ventricular septal defect and atrial septal defect, kidney

defects, and respiratory distress.

Zofran birth defect complaints which have been filed in federal courts from across the nation have been

transferred and consolidated to a single court, forming multidistrict litigation number 2657. Plaintiffs often

comment on the fact that Zofran was never FDA-approved to treat expectant mothers, or tested for safety on

these women and their unborn children. Despite this fact, however, manufacturer GlaxoSmithKline began to

market the drug in a controversial ?off-label? fashion to expectant mothers and Ob/Gyns across the U.S. as a

safe and effective morning sickness treatment.

The attorneys of Monheit Law are now working to assist other mothers who have taken Zofran and who have

gone on to give birth to children with defects. They want to help ensure that affected women will be given the

important opportunity to explore their legal rights in full. Affected women, children, and families may be

entitled to significant compensation, and may be able to join the current MDL. To better assist those wanting

to further explore their rights, the attorneys of Monheit Law are currently offering free legal consultations for

qualified parties.

To request additional information, or to ask questions, please contact Attorney Michael Monheit by calling

(877) 620-8411.

###

For more information about ZofranLegal.com, contact the company here:ZofranLegal.comMichael

Monheit1-877-620-8411michael@monheit.com1368 Barrowdale Road, Rydal, PA 19046

ZofranLegal.com

Sponsored by an alliance of attorneys, ZofranLegal.com is a resource for parents, families and birth defect survivors

interested in learning more about litigation surrounding the nausea drug Zofran and its link to increased risks of major

birth defects.

Website: http://zofranlegal.com/

Email: michael@monheit.com

Phone: 1-877-620-8411



Powered by PressAdvantage.com